

SPRING GROUP MEETING

Seattle

Cancer Survivorship Committee

APRIL 3-6, 2024 | SEATTLE, WASHINGTON

Cancer Control & Prevention Committees

Leadership

Vice-Chair NCORP: Dawn L. Hershman, MD, MS
 Cancer Care Delivery Co-Chairs: Dawn L. Hershman, MD, MS
 Scott D. Ramsey, MD, PhD
 Cancer Survivorship Co-Chairs: Halle C.F. Moore, MD
 Melinda L. Irwin, PhD, MPH
 Palliative & End of Life Co-Chairs: Robert S. Krouse, MD, FACS
 Marie Bakitas, DNSc, CRNP
 Prevention and Epidemiology Co-Chairs: Banu Arun, MD
 Marian L. Neuhouser, PhD, RD
 Symptom Control & QOL Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD
 Executive Officers: Katherine D. Crew, MD (CCD, Prevention,
 Symptom Control)
 Virginia Sun, PhD, MSN, RN (Palliative, Survivorship)
 Senior Advisor: Frank L. Meyskens, Jr., MD
 Statisticians: Katherine Guthrie, PhD
 Cathy Tangen, DrPH
 Joseph M. Unger, PhD
 Kathryn B. Arnold, MS
 Amy K. Darke, MS
 Danika Lew, MA
 Sarah Colby, MS
 Administrative Lead SDMC: Monica Yee, CCRP

Scientific Leadership

NCORP Representative: Scott Edward Delacrois, Jr., MD
 Helen Heng-Shan Moon, MD
 Radiation Oncology: Eileen P. Connolly, MD, PhD (CCD, Prevention)
 Kiri A. Cook, MD (Survivorship, Symptom Control)
 Erin F. Gillespie, MD (Symptom Control)
 Surgery Committee: Robert S. Krouse, MD, FACS
 Translational Medicine: James Rae, PhD
 Liaisons:
 Barlogie-Salmon Myeloma Committee: Charles S. Kuzma, MD
 Breast Committee: Mariya Rozenblit, MD (Survivorship)
 Helen K. Chew, MD (Symptom Control)
 Dawn Hershman, MD, MS (CCD)
 Banu Arun, MD (Prevention)
 Philip Lammers, MD
 Early Therapeutics & Rare Cancers: Lara E. Davis, MD (Survivorship)
 Jason M. Prosek, MD
 Gastrointestinal Committee: Jason A. Zell, DO (Prevention)
 Afsaneh Barzi, MD (CCD)
 Genitourinary Committee: Clara Hwang, MD
 Sarah P. Psutka, MD

International Liaison: Kathy S. Albain, MD
 Leukemia Committee: Stephanie B. Tsai, MD
 Lung Committee: Gary E. Goodman, MD
 Lymphoma Committee: Hayder Saeed, MD
 Melanoma Committee: Sancy Leachman, MD, PhD
 Thach-Giao Truong, MD (Survivorship)
 Recruitment & Retention: Allison M. Caban-Holt, PhD
 Digital Engagement: Jennifer R. Klemp, PhD (Survivorship)
 Krishna Soujanya Gunturu, MD (Survivorship)
 Mina S. Sedrak, MD (CCD)
 Katherine D. Crew, MD (Prevention)
 Michael J. Fisch, MD (Symptom Control)
 Veterans Affairs: Yeun-Hee Anna Park, MD (Symptom Control)
 Neha Patel, MD (Survivorship)
 Jacqueline Ann Gesek, BSN, RN (Nursing)

Designates

Oncology Research Professionals:

CRAs: Amanda R. Dinsdale, MHA, CCRC
 Amy Jo Koffarnus, BS, CCRP
 Samantha Wright, MS, CCRP
 Shirley S. Sui, BS
 Nurses: Connie Szczepanek, RN, BSN
 Melyssa W. Foust, MSN, RN
 Pharmaceutical Sciences Committee: Kimberly McConnell, PharmD
 Siu-Fun Wong, PharmD
 Sun "Coco" Yang, PharmD, PhD
 SDMC Data Coordinators: Kimberly Carvalho, BA
 Sam Dzingle, BA
 Matthew Eng, PharmD
 Diane Liggett, BS, CCRP
 Roxanne Topacio, CCRP
 Monica Yee, BA, CCRP
 Recruitment & Retention Specialist: Jamie Sundstrom, BS
 Patient Advocates: Barbara Segarra-Vazquez, DHSc (CCD)
 Amy Geschwender, PhD (Symptom Control)
 Hartley "Lee" M. Jones, MBA (Survivorship)
 Cheryl L. Jernigan, CPA (Prevention)
 Valerie Fraser (Palliative)
 Sr. Protocol Project Manager (CCD and Prevention): Patricia O'Kane
 Protocol Project Manager (Survivorship): Megan Keim
 Protocol Project Manager (Symptom Control): Justine Trevino
 Protocol Project Manager (Palliative Care): Andrea Garcia
 Clinical Trials Program Manager (Palliative Care): Laura Gildner, MS
 Clinical Trials Program Manager (CCD; Prevention;
 Survivorship; Symptom Control): Mariah Norman, MS

Cancer Survivorship Committee

Leadership

Co-Chairs: Melinda Irwin, PhD, MPH
 Halle Moore, MD

Time/Location

Friday, April 5, 2024 7:15 a.m. - 9:15 a.m.
 Room: Columbia D (Level 3)

Agenda

Welcome: Melinda Irwin and Halle Moore

Patient Advocate Update: Lee Jones

Updates:

Justin Floyd and Monika Leja: S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer."

Discussion

Suzie Zick and Heather Greenlee: Testing the Fatigue Reduction Diet in People with Early Stage Breast Cancer: A Randomized Controlled Trial, The GUIDE Study

Discussion

Rina Fox and Terry Badger: App-supported sleep coaching among cancer survivors and their bedroom partners

Discussion

Pragmatic Trial Emerging Concept

Krishna Gunturu: S2013 I-CHECKIT: Immune CHECKpoint Inhibitor Toxicity analysis (QOL and Symptom Control Committee)

Group: Late and lasting effects for cancer survivors following immunotherapy.

Liaison Updates/Other Business

Active Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. J. Floyd and M. Leja. Activated 9/15/2017. Temporarily Closed to new patient enrollments 2/1/24 for study redesign.

Concepts in Development

S2423, "Testing the Fatigue Diet in People with Early-Stage Breast Cancer: The GUIDE Study". Drs. S. Zick and H. Greenlee. Triage informally reviewed on 1/22/24. R01 application submitted February 8th.

XXXXX, "Randomized, phase II trial of vortioxetine for the reduction of ADT-induced cognitive impairment". Dr. L. Graham. Pending drug procurement plan.

XXXXX, "Phase III Trial of an App-Supported Sleep Coaching Intervention in Post-Treatment Survivors of Diverse Cancers and their Bedroom Partners". Drs. Rina Fox and Terry Badger. One-pager reviewed by DCP leadership on 1/26/24. Planned R01 submission for June deadline.

Closed Study

S1316, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Drs. R. Krouse, J. Denevee, and V. Sun. Activated: 3/9/15; Permanently Closed: 5/15/20.

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2023 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

IBCSG 48-14 Fertility preservation and assisted reproductive technologies in breast cancer patients interrupting adjuvant endocrine therapy to attempt pregnancy. Azim HA, Jr, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Satersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset Jablonski C, Borstnar S, Takei J, Eon Lee J, Walshe JM, Ruiz Borrego M, Moore HCF, Saunders C, Bjelic Radisic V, Susnjara S, Cardoso F, Klar NJ, Spanic T, Ruddy K, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Peccatori FA. Accepted/In press, 2024.

Submitted Manuscripts

None this cycle

Cancer Survivorship Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1501	A211901
Ascension Providence Hospitals - Southfield	4	-
Baptist Mem Health Care/Mid South MU-NCORP	7	-
Bay Area Tumor Institute NCORP	2	-
CWRU Case Comprehensive Cancer Center LAPS	14	-
Cancer Research for the Ozarks NCORP	11	-
City of Hope Comprehensive Cancer Center	49	-
Columbia University Minority Underserved NCORP	2	-
CommonSpirit Health Research Institute	1	-
Fred Hutchinson Cancer Research Center LAPS	4	-
Georgia NCI Community Oncology Research Program	13	-
Gulf South Minority Underserved NCORP	4	-
Heartland Cancer Research NCORP	20	-
Henry Ford Hospital	2	-
Kaiser Permanente NCI Comm Oncology Research Program	1	-
King Faisal Specialist Hospital and Research Centre	3	-
Lahey Hospital and Medical Center	6	-
Loyola University Medical Center	8	-
Medical U of South Carolina Minority Underserved NCORP	1	-
Michigan Cancer Research Consortium NCORP	3	-
Moffitt Cancer Center	23	-
Montana Cancer Consortium NCORP	1	-
NCORP of the Carolinas (Prisma Health NCORP)	2	-
National Cancer Center-Korea	1	-
New Mexico Minority Underserved NCORP	7	-
Oregon Health and Science University	1	-
UC Davis Comprehensive Cancer Center LAPS	2	-
USC Norris Comprehensive Cancer Center LAPS	4	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	1
University of Michigan Comprehensive Cancer Center LAPS	10	-
University of Utah - Huntsman Cancer Institute LAPS	-	2
Wayne State University - Karmanos Cancer Institute LAPS	6	-
ALLIANCE	23	-
ECOG-ACRIN	43	-
NRG	24	-
Total	309	3

